0Login
Agivog M 0.3 Tablet 15's
Agivog M 0.3 Tablet 15's belongs to the class of anti-diabetic drugs. It is used in the treatment of type 2 diabetes mellitus. Diabetes mellitus is a metabolic disease that causes high blood sugar levels. It occurs when the insulin (a hormone produced by the beta cells of the pancreas) is resistant in breaking the glucose to produce energy (insulin resistance) or the pancreas (an organ behind the stomach) produces little or no insulin at all.
Agivog M 0.3 Tablet 15's is composed of two medicines, namely Voglibose and Metformin. Voglibose belongs to the class of alpha-glucosidase inhibitors. It acts by inhibiting the intestinal enzymes, which break complex sugars into simple sugars such as glucose. This process prevents the rise of blood glucose levels. Metformin belongs to the class of biguanides and exhibits non-pancreatic effect to reduce serum glucose levels without increasing insulin secretion. It is also known as an insulin sensitizer as it increases the effects of insulin. Metformin is considered to be a unique anti-diabetic drug since it does not cause hypoglycemia (lowered blood sugar levels).
Take Agivog M 0.3 Tablet 15's with food at regular intervals as prescribed by your doctor. Your doctor will decide the dosage form, and this may change timely depending on your blood sugar levels. The common side effects of Agivog M 0.3 Tablet 15's include nausea, vomiting, changes in taste, diarrhoea, dizziness, stomach pain, shortness of breath, skin rash, bloating, and flatulence (intestinal wind/gas). Although not everyone experiences these side effects, if they occur, seek medical attention. Lactic acidosis, is a rare, but serious metabolic complication of excess lactic acid in the blood that is caused by metformin accumulation is reported. The risk of lactic acidosis is high in people with kidney, liver, and heart diseases.
Before starting Agivog M 0.3 Tablet 15's, let your doctor know if you have any medical history of anaemia (low hemoglobin levels), seizures (fits), heart, kidney, and liver diseases. Agivog M 0.3 Tablet 15's does not cause hypoglycemia (low blood sugar levels). However, when used with other diabetic drugs like insulin or sulfonylureas, it can lead to hypoglycemia. Also, speak to your doctor if you are on restricted food or fluid intake since Agivog M 0.3 Tablet 15's causes dehydration, low blood sugar, and kidney damage. Do not take Agivog M 0.3 Tablet 15's if you have gastrointestinal diseases like ulcerative colitis or Crohn’s disease. Do not take or stop Agivog M 0.3 Tablet 15's, if the doctor did not advise you to do so.
Agivog M 0.3 Tablet 15's is used to treat type 2 diabetes mellitus. It is a combination of Voglibose and Metformin. Voglibose belongs to the class of alpha-glucosidase inhibitors. It delays glucose absorption by inhibiting the intestinal enzymes, which break complex sugars into simple sugars such as glucose. This process prevents the rise of blood glucose levels immediately after meals. Metformin belongs to the class of biguanides. It shows the non-pancreatic effect to reduce serum glucose levels without increasing insulin secretion. It is also known as an insulin sensitizer as it increases the effects of insulin. It is considered to be a unique anti-diabetic drug since it does not lower blood sugar levels. Metformin does not cause weight gain in most cases.
Common side effects:
Rare side effects:
Agivog M 0.3 Tablet 15's may increase the risk of cardiovascular diseases and hypoglycemic conditions in renal and liver disease patients. It can cause pneumatosis intestinalis (gas-filled cysts on the bowel wall) when used along with other alpha-gastrointestinal drugs. It is advised to monitor the gastrointestinal side effects thoroughly to rule out the possibility of pneumatosis intestinalis. Agivog M 0.3 Tablet 15's has an increased risk of lactic acidosis (a rare, but serious metabolic complication of excess lactic acid in the blood that is caused by metformin accumulation). The risk of lactic acidosis is high in older people with kidney, liver, and heart diseases. Hence, brief your medical history and take advice from your doctor before starting Agivog M 0.3 Tablet 15's. Avoid consuming excessive alcohol as it can potentiate lactic acidosis.
Drug-Drug Interaction: Agivog M 0.3 Tablet 15's may interact with anti-depressants (selegiline, isocarboxazid, phenelzine), anti-inflammatory drugs (prednisolone, phenylbutazone), drugs that treat fluid retention (metolazone, hydrochlorothiazide, chlorothiazide), medicines used to treat high blood pressure (propranolol, metoprolol), anabolic, and corticosteroids. Please check the instruction leaflet that comes with the medication before you take Agivog M 0.3 Tablet 15's.
Drug-Food Interaction: Limit alcohol intake since it affects blood sugar levels. Avoid fatty foods and include healthy carbohydrates in your diet.
Drug-Disease Interaction: Tell your doctor before taking Agivog M 0.3 Tablet 15's if you have a medical history of allergic reactions to medicines, heart diseases, liver, and kidney problems. Agivog M 0.3 Tablet 15's may cause pneumatosis intestinalis (gas-filled cysts on the bowel wall) when used along with other alpha-gastrointestinal drugs.
Regular blood tests are recommended while taking Agivog M 0.3 Tablet 15's to monitor blood sugar levels.
Diabetes Mellitus type 2 is a condition in which either the body stops producing enough insulin (the hormone which helps to decrease sugar levels in the blood) or there is resistance to the action of insulin. As a result, excessive insulin is produced but it fails to act on the organs of the body. Symptoms of type 2 diabetes include feeling exhausted all time, feeling thirsty, having blurry vision, and the urge to urinate (pee) more often. Complications of type 2 diabetes include skin infection, eye problems (retinopathy), nerve damage (neuropathy), delayed wound healing, diabetic foot (foot ulcer), kidney disease (nephropathy), high blood pressure, and even stroke. Both low and high blood sugar levels can be dangerous and should be treated as soon as possible. Your H1bA1C below 5.7% is normal, 5.7-6.4% confirms the prediabetes stage, and 6.5% or greater states diabetes condition.